The CDMO plans to build and expand small, medium, and large manufacturing facilities across Europe and the U.S. over the next three years to meet rising demand for peptides.
David Ricks told Fox Business on Friday that it will be “easier” for Lilly to manufacture orforglipron at scale in the United States than the injectable GLP-1 medicines.
